What's new in
Multiple Sclerosis:

Diagnosis and treatment updates

Thursday, March 19th 2026. 6.30pm
TBC

This is a hybrid meeting.
Webinar details will be sent following registration.

Agenda

6.30pm - 6:45pm

Registration, welcome and refreshments

6.45pm - 7.30pm
Speaker:


Dr Hugh Kearney
Clinical Neurologist, St James Hospital, Dublin.

Topic:

TBC.

7:30pm - 7:50pm
Speaker:


Dr Audrey Reynolds
SpR, Tallaght University Hospital, Dublin.

Topic:

Long Term Efficacy and Safety Data Of BRIUMVI® in Relapsing Multiple Sclerosis.

7.40pm - 8.00pm

Q&A

▼ This medicinal product is subject to additional monitoring. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance website www.hpra.ie.  Adverse events can also be reported to Neuraxpharm Ireland by email at pv-ireland@neuraxpharm.com.

This meeting is sponsored by Neuraxpharm Ireland. This is a promotional meeting for Healthcare Professionals only and is organised and funded by Neuraxpharm Ireland. The content will include reference to BRIUMVI®. Further information on BRIUMVI® can be found at www.medicines.ie or by contacting Neuraxpharm Ireland, 4045 Kingswood Road, Dublin 24 Tel 01 428 7777.

© 2024 TG Therapeutics, Inc. All rights reserved. BRIUMVI® is a registered trademark of TG. Therapeutics, Inc.
Date of preparation: February 2026 | XXX.